(Q39794940)

14 September 2017

The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark (English)

1 reference

14 September 2017

1 reference

William E Fisher

1

1 reference

14 September 2017

1 August 2011

1 reference

14 September 2017

World Journal of Surgery

1 reference

14 September 2017

35

1 reference

14 September 2017

8

1 reference

14 September 2017

1766-1769

1 reference

https://scigraph.springernature.com/pub.10.1007/s00268-010-0949-7

14 September 2017

0 references

cites work

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS00268-010-0949-7

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-010-0949-7

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-010-0949-7

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-010-0949-7

A physical map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-010-0949-7

The complete genome of an individual by massively parallel DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-010-0949-7

The Sequence of the Human Genome

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21222122

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21222122

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00268-010-0949-7

1 reference

14 September 2017

1 reference

PubMed ID

21222122